Aditxt (NASDAQ:ADTX) stock is on the rise after the company announced a significant update regarding a clinical trial conducted by its subsidiary Pearsanta. According to a recent press release, Pearsanta has submitted a proposal to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense for a Clinical Trial Translational Endpoints Research Award.
The proposal aims to validate a new assay based on Pearsanta’s Mitomic Technology for the early detection of ovarian cancer. Chris Mitton, president of Pearsanta, expressed optimism about the potential impact of this technology, stating, “Our proprietary Mitomic Technology aims to provide a reliable, non-invasive, and effective blood test that can lead to earlier detection, more effective treatments, and, ultimately, save lives.”
ADTX Stock Movement Today
Following this news, there has been a surge in trading of ADTX stock, with over 97 million shares changing hands, a significant increase from its daily average of 615,000 shares. As of Wednesday afternoon, ADTX stock is up by 48.8%.
Stay tuned for more updates on the stock market, including news on Novo Nordisk (NYSE:NVO) stock, Sunrun (NASDAQ:RUN) stock, and political trades.
Analysis
The announcement of a potential breakthrough in early cancer detection through Aditxt’s subsidiary Pearsanta’s Mitomic Technology has sparked investor interest and led to a substantial increase in ADTX stock price. If successful, this technology could revolutionize cancer screening and treatment, potentially saving lives. Investors should monitor further developments in this clinical trial and assess the long-term impact on Aditxt’s stock performance.
Source: Shutterstock / PopTika